|
GBT-Grupo Biotoscana, a leading biopharmaceutical company in Latin America, announced the acquisition of Laboratorio DOSA S.A., a specialty pharmaceutical manufacturer based in Argentina. The transaction continues to advance GBT’s strategic agenda and expands GBT’s scope into the promising area of severe lung diseases. The bulk of DOSA’s products treat severe pulmonary pathologies including idiopathic pulmonary fibrosis and cystic fibrosis and it has additional portfolios in oncology, hematology and HIV. Laboratorio DOSA posted revenues of ARS 326 million (aprox. BRL 61 million) in 2016, up from ARS 228 million (aprox. BRL 42 million) in 2015.
The operation was closed at a price of USD 29.9 million. (approx. BRL 100 million), of which USD 20.7 million were paid in cash, USD 5 million were deposited in an escrow account which will be freed in 2022 and USD 4.2 million which will be paid in annual payments along the following 4 years.
"The announcement is an important milestone for us, as GBT continues to advance its strategic agenda and consolidates its position as the first pan-Latin American advanced medicines company," said Mariano GarcíaValiño, chief executive officer of the group. "The acquisition will enhance GBT’s product portfolio add further in-house R&D and manufacturing capabilities, strengthen our product renewal pipeline and provide us with a new platform for growth and geographic expansion."
"The combination with GBT will help DOSA reach a number of key countries where the companies’ products have significant potential" said Carlos Estevez, chief executive officer of DOSA. "We will also have the opportunity to introduce GBT and DOSA products to each other’s markets and customers."
GBT will retain Estevez as a special advisor, focusing in pipeline and product development.
Severe pulmonary diseases are one of the fastest-growing segment of the global pharmaceutical sector, according to a recent study by Allied Market Research. In particular, the study cites that global idiopathic pulmonary fibrosis market generated USD 1,616 million in 2016. The major factors that drive the growth of the global idiopathic pulmonary fibrosis market include rise in prevalence of fibrotic disease and increase in geriatric population. In addition, surge in demand for cost-effective drugs and introduction of advanced treatment options propel the market growth. GBT will seek to capitalize on this significant opportunity by further expanding its regional footprint and diversifying its product portfolio through in-licensing and proprietary R&D.
|